$JNP News
Last published 5y ago
- 5y agoGNLNLGLJNPGreenlane Appoints Director Donald Hunter as Chairman of the BoardACCESS NewswireCompany Reaffirms Commitment to Strong Corporate Governance and Independent Board Oversight BOCA RATON, FL / ACCESSWIRE / October 4, 2021 / Greenlane Holdings, Inc. ("Greenlane" or "the Company") (NASDAQ:GNLN), one of the largest global sellers of premi
- 5y agoBIIBJNPAtalanta Therapeutics Launches With $110 Million to Pioneer RNAi Therapeutics for Neurodegenerative DiseasesBusiness WireBOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, launched today with a Series A financing exclusively by F-Prime Capital. Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group. The total committed funding at launch with the upfront paymen ...
- 8y agoCTLTJNPCatalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals, Inc.Business WireSOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the successful completion of the previously announced tender offer by Catalent Boston, Inc. (“Merger Sub”), a subsidiary of Catalent Pharma Solutions, Inc. (“Parent”), Cat ...
- 8y agoCTLTJNPCORRECTING and REPLACING Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.Business WireSOMERSET, N.J.--(BUSINESS WIRE)--Reissuing release dated July 03, 2018 to correct Juniper Pharmaceuticals, Inc. ticker symbol in first sentence of first paragraph.
- 9y agoJNPJuniper Pharmaceuticals' (JNP) CEO Alicia Secor on Q3 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoJNPRobbins Arroyo LLP Is Investigating the Officers and Directors of Juniper Pharmaceuticals, Inc. on Behalf of ShareholdersBusiness WireSAN DIEGO & BOSTON--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Juniper Pharmaceuticals, Inc. (NASDAQGS: JNP) violated federal securities laws by issuing materially misleading information to the investing public. Juniper Pharmaceuticals focuses on developing therapeutics that address unmet medical needs in women's healt ...
- 10y agoJNPJuniper Pharmaceuticals' (JNP) CEO Frank Condella on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts